Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lifecare ASAFRA:LFC0 +79.29%9 Debt-to-Equity is 1.43 as of Mar. 2026, which is 921% above its 10-year median of 0.14. GuruFocus rates FRA:LFC0 with a GF Score™ of 9/100 and a GF Value™ of €0.24 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 700 Medical Devices & Instruments companies, Lifecare ASA ranks worse than 91.43% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lifecare ASA's Debt-to-Equity or its related term are showing as below:
FRA:LFC0'
s Debt-to-Equity Range Over the Past 10 Years
Min: -7.63 Med: 0.14 Max: 1.43
Current: 1.43
During the past 11 years, the highest Debt-to-Equity Ratio of Lifecare ASA was 1.43. The lowest was -7.63. And the median was 0.14.
FRA:LFC0's Debt-to-Equity is ranked worse than 91.43% of 700
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs FRA:LFC0: 1.43
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lifecare ASA Debt-to-Equity Related Terms
Lifecare ASA Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Lifecare ASA's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LFC0 vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Lifecare ASA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecare ASA Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lifecare ASA's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lifecare ASA's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecare ASA (FRA:LFC0) has a Debt-to-Equity of 1.43 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lifecare ASA and its competitors. This is 921% above median its historical median of 0.14. According to the industry distribution chart, Lifecare ASA ranks #640 out of 700 companies in the Medical Devices & Instruments industry, placing it in the top 91.4%.
Is Lifecare ASA's Debt-to-Equity too high?
Lifecare ASA's current Debt-to-Equity of 1.43 is 921% above median its 10-year median of 0.14. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Lifecare ASA's value of 1.43 is 521.7% above this industry median. Based on the distribution chart, Lifecare ASA ranks #640 out of 700 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lifecare ASA has a GF Score™ of 9/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifecare ASA's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lifecare ASA ranks #640 out of 700 companies for Debt-to-Equity. This places Lifecare ASA in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Lifecare ASA's value of 1.43 is 521.7% above this benchmark. While the company's 10-year median is 0.14 vs. the industry median of 0.23, Lifecare ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecare ASA's current Debt-to-Equity of 1.43 is 521.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lifecare ASA and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecare ASA's current Debt-to-Equity is 1.43, which is 921% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecare ASA stock overvalued right now?
Based on GuruFocus' analysis, Lifecare ASA (FRA:LFC0) is currently considered Possible Value Trap. The stock's GF Value™ is €0.24, compared to a current price of €0.03 — trading 89.5% below its estimated fair value. The current Debt-to-Equity is 1.43, which is 921% above median its 10-year median of 0.14 and 521.7% above the Medical Devices & Instruments industry median of 0.23. Lifecare ASA's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lifecare ASA (FRA:LFC0), the current Debt-to-Equity is 1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecare ASA (FRA:LFC0) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecare ASA stock appears to be undervalued.
The current stock price of €0.03 is trading 89.5% below its estimated GF Value™ of €0.24.
GuruFocus considers Lifecare ASA to be Possible Value Trap.
Key valuation signals for FRA:LFC0:
Debt-to-Equity: 1.43 (921% above median its 10-year median of 0.14)
GF Value™: €0.24 vs. price of €0.03 (89.5% below fair value)
Industry Position: 521.7% above the Medical Devices & Instruments median (#640 of 700)
No single metric tells the full story. See the FRA:LFC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. It is focused on advancing continuous glucose monitoring systems and uses osmotic pressure as a sensing method. Its technology can be applied to detect and monitor various analytes and molecules in humans and animals. The company operates as a single segment focused on research and development (R&D) of its osmotic pressure sensor and related components.
9GF Score
Get the complete analysis for FRA:LFC0
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LFC0 has been successfully added to your 
